Navigation Links
Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
Date:1/18/2008

First and only medication approved to reduce both A1C and LDL cholesterol

PARSIPPANY, N.J., Jan. 18 /PRNewswire/ -- Daiichi Sankyo, Inc., announced today that the United States Food and Drug Administration (FDA) has approved Welchol(TM) (colesevelam HCl) to improve glycemic control (measured as hemoglobin A1C) in adults with type 2 diabetes mellitus in combination with metformin, sulfonylureas, or insulin, either alone or in combination with other anti-diabetic agents. Welchol is now the first and only medication approved to reduce both glucose levels and low density lipoprotein cholesterol levels (LDL-C). The ADA estimates that 20.8 million people in the United States have diabetes with more than 90 percent of these people having type 2 diabetes.(1) Forty percent of patients with type 2 diabetes also have high LDL-cholesterol.(2) Welchol is a new option that addresses both these chronic health conditions and provides physicians with a unique therapeutic approach for treating patients with type 2 diabetes.

Pivotal data presented at the American Diabetes Association's (ADA) 67th Annual Scientific Sessions in Chicago in June, 2007 demonstrated that Welchol can lower both A1C and LDL-C levels in patients with type 2 diabetes who were uncontrolled on a metformin-based regimen. Patients in the study were randomly assigned to two groups. The addition of Welchol was compared to the addition of placebo in patients on a metformin-based regimen. The addition of Welchol (n=79) to pre-existing metformin monotherapy achieved a significant mean reduction in A1C levels of 0.47 percent relative to placebo (p<0.0024). Further, the total Welchol treatment group, when treated with either metformin monotherapy or metformin-combination therapy, achieved significantly greater reductions in A1C levels compared to placebo (mean reduction of 0.54%, p<0.001). The study further demonstrated that the total Welchol treatment group achieved significantly lower LDL-C levels comp
'/>"/>

SOURCE Daiichi Sankyo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. MultiVu Video Feed: WELCHOL (R) (COLESEVELAM HCL) RECEIVES FDA APPROVAL FOR GLUCOSE CONTROL IN ADULTS WITH TYPE 2 DIABETES MELITUS
2. Novadaqs SPY System receives clearance for use in organ transplant surgery
3. BeneChills RhinoChill System Receives CE Marking for European Commercial Sale
4. e-Health Card Terminal From SCM Microsystems Receives GEMATIK Certification
5. Breckenridge Pharmaceutical Settles Paragraph IV Litigation and Receives FDA Approval for its Oxcarbazepine ANDA
6. LifeMasters Receives Full URAC Disease Management Accreditation
7. Federal Government Receives Failing Grades on Tobacco Control in Annual American Lung Association Report
8. Glory Foods Receives Heart Healthy Certification
9. TeamStaff Receives Nasdaq Determination Letter
10. Gary Tschautscher of Nonin Medical, Inc. Receives CEO of 2007 for North American Patient Monitoring From Frost & Sullivan
11. Ocera Therapeutics Receives Orphan Drug Status for AST-120 for Pouchitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... A 2014 study supported by the ... has found that rising temperatures and hotter ... children developing kidney stones. Researchers based their findings ... U.S. cities, including Dallas, Atlanta, Philadelphia, Chicago and Los ... for kidney stones within a relatively short span – ...
(Date:9/23/2014)... 23, 2014 ClickFunnels 2.0 ... application has created a buzz of excitement throughout the ... this new software has caught the attention of HonestyFirstReviews.com’s ... her readers. , “The technical aspects of ... and development can be quite daunting,” reports Hendricks. “In ...
(Date:9/23/2014)... from the University of Toronto, directed by Drs. ... in normal vestibular nerves and vestibular schwannomas (VSs). ... negligible difference between VSs that sporadically occur and ... a genetic disorder; and 2) the overexpressed PI3K/AKT/mTOR ... excellent therapeutic target. Detailed findings of this study ...
(Date:9/23/2014)... PA (PRWEB) September 23, 2014 Rinovum ... home-use conception assistance device on the market cleared by ... in stores and online at http://www.storkotc.com . , ... dream of having a baby is delayed by infertility1 ... first step to optimize their chances to conceive. ...
(Date:9/23/2014)... 2014 Ale Gicqueau, President and Chairman ... Data Visualization for Clinical Trials at the upcoming ... Francisco on Friday, September 26, 2014. , PhUSE ... its inception, PhUSE has expanded from its roots as ... platform for the discussion of topics encompassing the work ...
Breaking Medicine News(10 mins):Health News:New Study Finds Link Between Higher Temperatures and Kidney Stones in the United States 2Health News:New Study Finds Link Between Higher Temperatures and Kidney Stones in the United States 3Health News:ClickFunnels 2.0 – Review Of Russell Brunson’s Sales Funnel Building Software Released 2Health News:Aberrant PI3K/AKT/mTOR pathway found in vestibular schwanommas may be therapeutic target 2Health News:Aberrant PI3K/AKT/mTOR pathway found in vestibular schwanommas may be therapeutic target 3Health News:First-Ever Conception Assistance Device FDA-Cleared for Home Use Launches U.S. OTC Sales -- The Stork® OTC Delivers Hope to Millions Struggling to Conceive A Child 2Health News:First-Ever Conception Assistance Device FDA-Cleared for Home Use Launches U.S. OTC Sales -- The Stork® OTC Delivers Hope to Millions Struggling to Conceive A Child 3Health News:First-Ever Conception Assistance Device FDA-Cleared for Home Use Launches U.S. OTC Sales -- The Stork® OTC Delivers Hope to Millions Struggling to Conceive A Child 4Health News:Clinovo Sponsors and Presents at Pharmaceutical Users Software Exchange (PhUSE) SDE in San Francisco 2
... , ... Automates Consumer Tracking and Claims Workflow to Help Organizations Take Control of Medicaid Waivers ... Reston, ... in integrated health and human services management, announced today the immediate availability of ...
... ... also understands the value of providing excellent customer service to their customers. The customer ... A recent award from third party evaluators at STELLAService, ranks Anjolee high in three ... ...
... ... increase in business as the reward for providing personalized service and customized medications. The ... medicine. , ... Scottsdale, AZ (PRWEB) May 5, 2010 -- While important veterinary drugs remain in ...
... ... Yagodich – podiatrists at Your Next Step in Ardmore and Paoli, Pennsylvania – excitedly ... patients that suffer from toenail fungus. , ... Ardmore and Paoli, Pennsylvania (Vocus) May 4, 2010 -- ...
... ... and teff provide important nutrients for the gluten-free diet, but Carol Fenster bakes with sorghum ... To celebrate May as National Celiac Awareness month, she offers a free sorghum-based cookbook, Gluten-Free ... , ...
... helped some with respiratory disease, but more study ... Treatment with the antibiotic azithromycin doesn,t improve the ... fibrosis, U.S. researchers report. , "A vicious cycle ... and premature death in patients with cystic fibrosis ...
Cached Medicine News:Health News:Harmony Information Systems Announces Availability of Harmony for Aging Waivers Edition 2Health News:Harmony Information Systems Announces Availability of Harmony for Aging Waivers Edition 3Health News:Anjolee Receives Stellar Customer Service Award from STELLAService 2Health News:Scottsdale Veterinary Pharmacy Celebrates Success in Business By Dodging Veterinary Drug Shortages 2Health News:Scottsdale Veterinary Pharmacy Celebrates Success in Business By Dodging Veterinary Drug Shortages 3Health News:Over 450 Patients Now Toenail Fungus Free Thanks to Your Next Step's New Toenail Fungus Laser Treatment Technology 2Health News:Carol Fenster Offers Tips for Gluten-Free Cooking with Sorghum: May is National Celiac Awareness Month 2Health News:Azithromycin Doesn't Always Help Lungs in Cystic Fibrosis Patients 2
(Date:9/22/2014)... Sept. 22, 2014 Children,s National Health ... Sept. 29 at 5 p.m. EDT for its ... in response to continued strong interest from inventors.  ... will be awarded to the winning presentations at ... Symposium hosted by Children,s National in October. For ...
(Date:9/22/2014)... and SHANGHAI , Sept. ... (BHG), a global knowledge leader in healthcare technology, ... to support healthcare innovation in China ... connected health technologies. Continua and BHG announced this ... being held this week in Washington, ...
(Date:9/22/2014)... , Sept. 22, 2014 ... of the "Global Ablation Technologies (Radiofrequency, Ultrasound, ... 2019" report to their offering. ... the global ablation technologies market has been divided ... ultrasound, microwave, cryotherapy, hydrothermal, and hydromechanical ablation technologies. ...
Breaking Medicine Technology:Calling all medical innovators: Submit your pediatric medical device pitch for Children's National competition by Sept. 29 2Calling all medical innovators: Submit your pediatric medical device pitch for Children's National competition by Sept. 29 3Continua and Borderless Healthcare Group Form Strategic Partnership, Launch the Healthcare Technology Innovation Center in Shanghai 2Continua and Borderless Healthcare Group Form Strategic Partnership, Launch the Healthcare Technology Innovation Center in Shanghai 3Continua and Borderless Healthcare Group Form Strategic Partnership, Launch the Healthcare Technology Innovation Center in Shanghai 4Global Ablation Technologies (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave) Market - Forecasts to 2019 2Global Ablation Technologies (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave) Market - Forecasts to 2019 3
The Select Series® Arterial Cannulae utilize a state-of-the-art dip-molding technology. This process allows molding of a one-piece, wire-wound cannula that is flexible and kink-resistant....
Intermittent catheter...
... assay is a rapid and accurate bedside test ... assisting the diagnosis and assessment of patients with ... speed and accuracy profit from a ... assay = 12 minutes. In emergency departments Point ...
... Focus from Thermo Labsystems was designed specifically ... Advanced features such as the new fast ... on microvolumes help to define this as ... The new interchangeable handle plate offers a ...
Medicine Products: